Hypertensive nephropathy: prevention and treatment recommendations

Bibliography

• Available from: www.usrds.org/2009/pdf vol.3
   Google Scholar
• Fervanca FC, Textor SC, Rosenthal D. Nephrosclerosis. Available from: http://edmedicine.medscape.com [Last accessed 23 March 2010]
   Google Scholar
• Klag MJ, Whelton PK, Randall BL, Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-8
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Chua DC, Bakris GL. Is proteinuria a plausible target of therapy? Curr Hypertens Rep 2004;6:177-81
   PubMedGoogle Scholar
• Culleton BF, Larson MG, Parfrey PS, Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000;109:1-8
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003;42:1050-65
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290
   PubMed Web of Science ®Google Scholar
• Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706
   PubMed Web of Science ®Google Scholar
• Brod J, Bahlmann J, Cachovan M, Mechanisms for the elevation of blood pressure in human renal disease. Preliminary report. Hypertension 1982;4:839-44
   PubMed Web of Science ®Google Scholar
• Bidani AK, Hacioglu R, Abu-Amarah I, ‘Step’ vs. ‘dynamic’ autoregulation: implications for susceptibility to hypertensive injury. Am J Physiol Renal Physiol 2003;285:F113-20
   Google Scholar
• Grisk O, Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 2004;61:238-46
   PubMedGoogle Scholar
• Garg JP, Ellis R, Elliott WJ, Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol 2005;25:393-9
   PubMed Web of Science ®Google Scholar
• Safar M, Chamiot-Clerc P, Dagher G, Renaud JF. Pulse pressure, endothelium function, and arterial stiffness in spontaneously hypertensive rats. Hypertension 2001;38:1416-21
   PubMed Web of Science ®Google Scholar
• Safar M, Laurent S, Safavian A, Sodium and large arteries in hypertension. Effects of indapamide. Am J Med 1988;84:15-9
   PubMedGoogle Scholar
• Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047-51
   PubMedGoogle Scholar
• Freedman BI, Hicks PJ, Bostrom MA, Polymorphism in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end stage renal disease historically attributed to hypertension in African American. Kidney Int 2009;75:736-45
   PubMed Web of Science ®Google Scholar
• Freedman BI, Kopp JB, Winkler CA, Polymorphism in the non-muscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol 2009;26:626-32
   Google Scholar
• Salem RM, Cadman PE, Chen Y, Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 2008;19:600-14
   PubMed Web of Science ®Google Scholar
• Chen Y, Rao F, Rodriguez-Flores JL, Naturally occurring human genetic variation in the 3′-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol 2008;52:1468-81
   PubMed Web of Science ®Google Scholar
• Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006;26:635-53, vi
   PubMedGoogle Scholar
• Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 2004;6:352-6
   PubMedGoogle Scholar
• Giner V, Tormos C, Chaves FJ, Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004;255:588-94
   PubMed Web of Science ®Google Scholar
• Kistorp C, Raymond I, Pedersen F, N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-16
   PubMed Web of Science ®Google Scholar
• Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003;16:952-8
   PubMed Web of Science ®Google Scholar
• Steinke JM, Sinaiko AR, Kramer MS, The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-71
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005;46:1309-15
   PubMedGoogle Scholar
• Eknoyan G, Hostetter T, Bakris GL, Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003;42:617-22
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006;70:1214-22
   PubMed Web of Science ®Google Scholar
• Atkins RC, Briganti EM, Lewis JB, Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-7
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20
   PubMed Web of Science ®Google Scholar
• Lea J, Greene T, Hebert L, The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:947-53
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-64
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP, Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L, Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26
   PubMed Web of Science ®Google Scholar
• Toto RD. Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent? Curr Hypertens Rep 2005;7:374-8
   PubMedGoogle Scholar
• Khosla N, Kalaitidis R, Bakris GL. The kidney, hypertemsion and remaining challenges. Med Clin N Am 2009;93:697-715
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB, Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Greene T, Wang X, The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Loriga G, Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46
   PubMed Web of Science ®Google Scholar
• Appel LJ, Wright JT Jr, Greene T, Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008;168:832-9
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52
   PubMed Web of Science ®Google Scholar
• Mishra SI, Jones-Burton C, Fink JC, Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005;7:385-91
   PubMedGoogle Scholar
• Sacks FM, Svetkey LP, Vollmer WM, Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Gherardi G, Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998;352:1252-6
   PubMed Web of Science ®Google Scholar
• Rahman M, Pressel S, Davis BR, Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-46
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueeen M, Renal outcomes with Telmisartan, ramipril, or both, in people at high risk (the ONTARGET study): a multicentre, randomized, double blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 2004;24:168-75
   PubMed Web of Science ®Google Scholar
• Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008;(4):CD007066
   Google Scholar
• Parving HH, Persson F, Lewis JB, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Aliskiren Trial in Type 2 Diabetes using cardio-renal endpoints: rationale and study design. Nephrol Dial Transplant 2009;24:1663-71
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S, Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45
   PubMed Web of Science ®Google Scholar
• Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008;51:199-211
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMedGoogle Scholar
• Wing LM, Reid CM, Ryan P, A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92
   PubMed Web of Science ®Google Scholar
• Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich) 2005;7:354-6
   PubMedGoogle Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
   PubMed Web of Science ®Google Scholar
• Eriksson JW, Jansson PA, Carlberg B, Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008;52:1030-7
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Zhou Q, Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr 2008;3:18-25
   PubMedGoogle Scholar
• Bakris G, Molitch M, Hewkin A, Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7
   PubMed Web of Science ®Google Scholar
• Bakris G, Stockert J, Molitch M, Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009;11:177-87
   PubMedGoogle Scholar
• Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595-605
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-23
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Eng J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
   Google Scholar
• Bakris GL, Weir MR, Secic M, Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002
   PubMed Web of Science ®Google Scholar
• Toto RD. Management of hypertensive chronic kidney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich) 2005;7:15-20
   PubMedGoogle Scholar
• Boero R, Rollino C, Massara C, Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. J Nephrol 2001;14:15-8
   PubMedGoogle Scholar
• Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 2005;46:637-42
   PubMed Web of Science ®Google Scholar
• Bakris GL, Copley JB, Vicknair N, Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50
   PubMed Web of Science ®Google Scholar
• Bakris GL, Mangrum A, Copley JB, Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-50
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, Shanifar S, Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65
   PubMed Web of Science ®Google Scholar
• Kalaitzidis R, Bakris G. Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant 2009;24:701-2
   Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
   PubMed Web of Science ®Google Scholar
• Kumar KV, Shifow AA, Naidu MU, Ratnakar KS. Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci 2000;66:2603-11
   PubMed Web of Science ®Google Scholar
• Singh D, Chander V, Chopra K. Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am J Nephrol 2003;23:415-21
   PubMed Web of Science ®Google Scholar
• Rachmani R, Levi Z, Slavachevsky I, Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 1998;80:175-82
   PubMed Web of Science ®Google Scholar
• Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42:239-46
   PubMed Web of Science ®Google Scholar